

MHTX And Dr. Edward Flynn Interviewed By Bloomberg Radio To Discuss Early Detection of Breast Cancer

Detection Possible Three Years Earlier Than Current Mammograms Without Radiation Or Discomfort

January 27, 2011

"With this biomagnetic imaging technique, it is possible to identify and image small clusters of cancer cells, providing the ability to find cancer at a substantially earlier stage than is presently possible and without using radiation."

ALBUQUERQUE, N.M.--Technology exists today that is capable of detecting breast cancer up to three years earlier than current mammogram technology, Manhattan Scientifics (OTCBB:MHTX) Founder Marvin Maslow and nuclear physicist Edward R. Flynn, PhD said in a recent Bloomberg Radio interview. The work of Dr. Flynn, who is a principal developer of the Magnetic Relaxometry technology that enables early cancer detection, has been funded by Phase II Small Business Innovative Research grants from the NIH, and has been exclusively licensed to Manhattan Scientifics.

Flynn's technology is a non-radiation diagnostic that uses magnetic, nano-sized breast cancer targeting antibodies which bind only to cancer, and can detect and localize a tumor with significantly fewer breast cancer cells.

"It takes 50,000 cells using our technology (Magnetic Relaxometry) for us to see a tumor. It takes 100 million cells before a mammogram sees it," commented Dr. Flynn. "That's why we can detect a breast cancer tumor up to three years before a mammogram can."

Dr. Flynn added that the technology is based on the use of sophisticated magnetic field sensors to measure extremely small magnetic fields emitted by magnetic nanoparticles attached to known breast cancer antibodies that bind only to breast cancer cells. "Essentially a "magnetic moment" is created, yielding high contrast images of tumors compared to normal cells," said Flynn. "With this biomagnetic imaging technique, it is possible to identify and image small clusters of cancer cells, providing the ability to find cancer at a substantially earlier stage than is presently possible and without using radiation."

According to Marvin Maslow, nanotechnology, and the emerging field of nanomedicine, promise to change how—and when—we can detect many different cancers.

"This biomagnetic sensor method is applicable to breast, ovarian, leukemia, prostate and potentially other cancers," he commented.

The entire interview can be heard at <http://www.mhtx.com/media/>.

About Manhattan Scientifics

Manhattan Scientifics, Inc., (OTCBB: MHTX), is a leading information age enterprise focused on the nanomedicine space. Located in New Mexico, New York and Montreal, Manhattan Scientifics'



goal is to create profit for the company's shareholders through royalty-bearing licenses with Fortune 1000 companies by marketing products that rely on the company's patents, know-how and intellectual property. Manhattan Scientifics owns the exclusive, perpetual U.S. license to a family of patents which will enable the manufacture and marketing of super strong, ultra light-weight "nanostructured" metals that have been developed at the Los Alamos National Laboratory (LANL) and in the former Soviet Union. More information about Manhattan Scientifics can be found at www.mhtx.com and at www.seniorscientific.com

Forward-looking statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Contacts

Manhattan Scientifics, Inc.

Marvin Maslow, Director of PR & IR, 917-923-3300

Email: marvin@mhtx.com

U.S. & Canadian Investor Relations

Hawk Associates: Frank Hawkins, 305-451-1888

Email: f.hawkins@hawkassociates.com